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Lysophosphatidic acid (LPA) activates a family of cognate G protein-coupled receptors and is involved in
various pathophysiological processes. However, it is not clearly understood how these LPA receptors are
specifically coupled to their downstream signaling molecules. This study found that LPA2, but not the other
LPA receptor isoforms, specifically interacts with Na/H exchanger regulatory factor2 (NHERF2). In addi-
tion, the interaction between them requires the C-terminal PDZ domain-binding motif of LPA2 and the second
PDZ domain of NHERF2. Moreover, the stable expression of NHERF2 potentiated LPA-induced phospho-
lipase C- (PLC-) activation, which was markedly attenuated by either a mutation in the PDZ-binding motif
of LPA2 or by the gene silencing of NHERF2. Using its second PDZ domain, NHERF2 was found to indirectly
link LPA2 to PLC-3 to form a complex, and the other PLC- isozymes were not included in the protein
complex. Consistently, LPA2-mediated PLC- activation was specifically inhibited by the gene silencing of
PLC-3. In addition, NHERF2 increases LPA-induced ERK activation, which is followed by cyclooxygenase-2
induction via a PLC-dependent pathway. Overall, the results suggest that a ternary complex composed of LPA2,
NHERF2, and PLC-3 may play a key role in the LPA2-mediated PLC- signaling pathway.
Lysophosphatidic acid (LPA) is released by activated plate-
lets and by a wide variety of mammalian cells, including adi-
pocytes, fibroblasts, and endothelial cells, as well as by several
types of cancer cells (11, 36). Generated LPA acts as both an
autocrine and paracrine of cellular signaling in cells and elicits
numerous physiological responses such as cell proliferation,
survival, chemotaxis, platelet aggregation, smooth muscle con-
tractions, and tumor cell invasion (34).
LPA binds to members of the family of G-protein-coupled
receptor (GPCR), which are localized on the plasma mem-
brane. To date, three subtypes of the LPA receptor (EDG2,
EDG4, and EDG7) have been cloned (1, 4, 18, 22) and have
been renamed LPA1, LPA2, and LPA3 according to the
IUPHAR nomenclature system. Upon LPA stimulation, the
LPA receptors interact with the heterotrimeric G-proteins
(Gq/11, and Gi/o) and trigger the GDP/GTP exchange of their
 subunits. Subsequently, the dissociated G and  subunits
activate multiple effector systems, including phospholipase C-
(PLC-)/protein kinase C (PKC)/Ca2, RAS–Raf-1–mitogen-
activated protein (MAPK), and phosphatidylinositol 3-kinase,
but inhibit the adenylyl cyclase-cyclic AMP pathway (3, 4, 8, 22,
23). The LPA receptors also activate the small GTPase, RhoA
through G12/13, which leads to stress fiber formation and a
focal adhesion assembly (8, 23). These results suggest that
heterotrimeric G proteins play a key role in LPA-induced cell
signaling. In addition to the heterotrimeric G proteins, recent
reports have suggested that the PDZ (PSD-95/Disk-large/
ZO-1) domain-containing proteins play a role in regulating
GPCR-mediated signaling (15).
The Na/H exchanger regulatory factor (NHERF) family
proteins, i.e., NHERF1 and NHERF2, regulate intracellular
signal transduction by a PDZ domain-mediated interaction
with multiple target proteins and/or by the ERM-binding re-
gion-mediated interactions with the actin-binding proteins, i.e.,
ezrin, radixin, or moesin (6, 43, 45). The NHERF family pro-
teins contain two tandem PDZ domains, which are protein-
protein interaction domains that are associated with the spe-
cific C-terminal motifs on the target proteins (43, 45). It has
been reported that the first PDZ domain of NHERF1 prefer-
entially binds to the motif, D-S/T-X-L, at the end of target
proteins, such as 2-adrenergic receptor (D-S-L-L), P2Y1 pu-
rinergic receptor (D-T-S-L), and cystic fibrosis transmembrane
regulator (D-T-R-L) (16). In addition, by screening a random
peptide library, it was demonstrated that the first PDZ domain
of NHERF1 avidly binds to a consensus motif (S/T-R/Y-L) and
the second PDZ domain of NHERF1 interacts with a different
amino acid sequence (S-S/T-W-L) (44). This suggests that the
two PDZ domains of the NHERF family proteins may have a
distinct peptide-binding specificity. Although the binding spec-
ificity of NHERF2 has not been determined, several reports
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have suggested that NHERF2 may have a distinct binding
specificity and physiological function that are not duplicated by
NHERF1 (10, 21, 24, 47). In our previous study, it was ob-
served that NHERF2 but not NHERF1 specifically interacts
with PLC-3 and plays a key role in PLC-3 activation by the
PDZ domain-mediated interaction (21). By means of the PDZ
domain-mediated interaction, NHERF1 and/or NHERF2 in-
teract directly with the C-terminal PDZ domain-binding motifs
of several GPCRs, including the 2-adrenergic receptor (17),
the parathyroid hormone 1 receptor (31), and the P2Y1 puri-
nergic receptor (16). In addition to these GPCRs, two isoforms
of LPA receptors, LPA1 and LPA2, also harbor a PDZ-binding
motif (H-S-V-V and D-S-T-L, respectively) in their carboxyl
termini. However, it is not known whether both LPA receptors
and PLC-3 are included in a protein complex by the PDZ
domain-mediated interaction and whether LPA-induced PLC-
 activation is specifically regulated by the NHERF family pro-
teins.
The present study provides the first evidence that NHERF2
specifically interacts with LPA2 but not with the other LPA
receptor isotypes. In addition, it is shown that NHERF2 phys-
ically links PLC-3 to LPA2 and that the resultant ternary
complex is crucial for determining the amplitude and the spec-
ificity of LPA2-mediated PLC- activation.
MATERIALS AND METHODS
Materials. Lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycerol-3-phos-
phate) was purchased from Biomol (Plymouth Meeting, Pa.). Fluo-3/AM, Lipo-
fectamine, FuGene 6, and DSP (dithiobis[succinimidylpropionate]) were from
Molecular Probes, Invitrogen (Carlsbad, Calif.), Boehringer Mannheim (Mann-
heim, Germany), and Pierce (Rockford, Ill.), respectively. The cell culture dishes
and plates were obtained from BD Bioscience (Falcon). The serum and medium
were obtained from HyClone (Logan, Utah) and Gibco-BRL, and the other
chemicals were purchased from Sigma (St. Louis, Mo.) in extrapure grade.
Antibodies for immunoblotting. Rabbit polyclonal anti-NHERF1 and anti-
NHERF2 antibody were generated as previously described (29). The anti-gluta-
thione S-transferase (GST) and anti-MBP antibodies were purchased from New
England Biolabs, and anti-Flag antibody (M2 clone) was purchased from Sigma.
In addition, the specific antibodies to PLC-1, PLC-3, and phosphorylated
extracellular signal-regulated kinase (ERK) were obtained from the Santa Cruz
Co., and the anti-COX-2 antibody was acquired from Caymen Chemicals (Ann
Arbor, Mich.).
Cell culture and transfection. Monolayer cultures of the COS-7 cells (from
Gibco-BRL), HeLa cells, and Rat-1 cells (from the American Type Culture
Collection) were maintained in Dulbecco modified Eagle medium supplemented
with 10% fetal bovine serum. The cells were grown at 37°C in a humidified
atmosphere containing 5% CO2. For the transient expression, either COS-7 cells
or HeLa cells were plated at a density of 1.5  104 cells/cm2. The next day, the
cells were transfected with ca. 1 to 5 g of the total plasmid DNA by using a
Lipofectamine reagent according to the manufacturer’s instructions (Invitrogen).
For the stable expression of the various NHERF2 constructs, Rat-1 cells were
transfected by using the FuGene 6 reagent and the positive clones were then
selected by using the culture medium supplemented with the G418 reagents. The
stable expression level of the NHERF2 constructs was examined by Western blot
analysis.
Plasmid constructions and site-directed mutagenesis. Initially, the human
LPA2/EDG4 cDNA was cloned as a mutant form (GenBank accession number
AF011466) (1). Thereafter, Bandoh et al. and Contos et al. identified a G dele-
tion, in the 3 region of the previous cloned cDNA, which results in a frame-shift
mutation in the LPA2/EDG4 C-terminal region (3, 9). The corrected version of
the LPA2/EDG4 cDNA was deposited by them to the GenBank (GenBank
accession number AF233092). The present study used the Flag-tagged versions
of the wild-type human LPA1, LPA2, and LPA3, which were kindly provided by
J. Aoki (Tokyo University, Tokyo, Japan). It was also confirmed by automatic
sequencing that the nucleotide sequence of the wild-type LPA2 matched the
sequence deposited in the GenBank (accession number AF233092), perfectly. In
order to express the cytoplasmic tail (CT) of LPA1, LPA2, or LPA3 in Escherichia
coli, these cDNAs were also used as a template for PCR. The pairs of primers
used for PCR were 5-CCG GCC TTC CAG CGC AGT GAGT AAC CCC ACC
GG-3 and 5-ACGC GTCGAC CTA AAC CAC AGA GTG ATC ATT GCT
G-3 for LPA1, 5-CCG GAA TTC CTC CGC CAG TCC ACC CGC GAG
TC-3 and 5-ACGC GTC GAC CTA AAG GGT GGA GTC CAT CAG
TGG-3for LPA2, and 5-CCG GAA TTC TTC TCT CAG GAG AAC CCA
GAG AGG C-3 and 5-ACGC GTC GAC TTA GGA AGT GCT TTT ATT
GCA GAC TG-3 for LPA3. The PCR products were digested with EcoRI and
SalI enzyme and inserted into either pGEX4T-1 (Amersham Pharmacia Biotech)
or into pMAL-C2x (New England Biolabs). Various NHERF2 and NHERF1
constructs were generated as described previously (21). The site-directed mu-
tagenesis was performed by the PCR method (19). In order to substitute the
Leu351 with Ala (the DSTA mutant), the PCRs were performed by using a wild-
type LPA2 template DNA and the reverse primer 5-ATG CGC GGC CGC CTA
AGC GGT GGA GTC CAT CAG-3. All of the mutations were verified by
sequence analysis by using an ABI automated sequencer (Applied Biosystems).
It was also confirmed that no mutation on the other site(s) had occurred.
Pull-down assay. Pull-down assays were performed by the recombinant pro-
teins fused to either GST or the His6 epitope. The lysates were sonicated and
centrifuged at 10,000  g for 20 min. Equal amounts of the tissue or cell extracts
were incubated with either the Sepharose-bound GST-fusion proteins or the
Ni2-nitrilotriacetic acid resin-bound His6-tagged proteins. The beads and ly-
sates were rocked for 90 min at 4°C. After incubation, the beads were washed
three times in a lysis buffer (50 mM HEPES [pH 7.4] and 150 mM NaCl plus 1%
Triton X-100). The bound proteins were eluted with a 1 sodium dodecyl sulfate
(SDS) sample buffer supplemented with 50 mM dithiothreitol and 30 mM
EDTA, separated on SDS–10% polyacrylamide gels, transferred to nitrocellu-
lose membrane, and analyzed by standard Western blotting procedures.
Immunoprecipitation. The cells were lysed in a lysis buffer, allowed to immu-
noreact with the appropriate antibodies, and immobilized onto either the protein
A-Sepharose or -Flag affinity resin. The immunocomplexes were collected by
the centrifugation at 1,000  g and then washed four times with 1 ml of a lysis
buffer. The resulting precipitates were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) and were analyzed by using Western blot analysis.
Ca2 imaging analysis by confocal laser microscopy. Rat-1 cells were plated
for Ca2 imaging analysis in the adherent cells. One day later, the cells were
incubated with Fluo-3/AM (1 M; Molecular Probes) for 30 min and washed
twice with 1 ml of a prewarmed Ca2-free Locke’s solution (158.4 mM NaCl, 5.6
mM KCl, 1.2 mM MgCl2, 5 mM HEPES [pH 7.3], 10 mM glucose, 0.2 mM
EGTA). The intracellular calcium-dependent fluorescence was imaged under a
Zeiss LSM510 confocal laser microscope. The fluorescence intensity traces from
the individual cells were obtained by monitoring the average overall intensity of
the cell each by using Zeiss laser-scanning microscopy software. Fluo-3 was
excited by the 488-nm line from a krypton-argon laser, and the emission fluo-
rescence was monitored at 515 nm. For the Fluo-3 measurements, the contrast
and brightness levels were maintained at constant settings.
Knock-down by using siRNA transfections. Small interfering RNA (siRNA)
duplexes directed against NHERF1 (nucleotides 451 to 469), NHERF2 (nucle-
otides 862 to 880), PLC-1 (nucleotides 374 to 392), and PLC-3 (nucleotides
483 to 501) were synthesized by Dhamarcon, Inc. (Lafayette, Colo.). The presyn-
thesized control siRNA duplexes (Luciferase GL3 Duplex) were also purchased
and used as the control oligonucleotides. HeLa cells were transfected with 20 nM
oligonucleotide by using Oligofectamine in serum-free conditions according to
the manufacturer’s instructions. At 4 h after transfection, the cells were washed
and supplemented with fresh medium containing 10% fetal bovine serum. The
cells were incubated for 72 h prior to use.
Adenoviral infections. The recombinant adenovirus, expressing the Flag-
LPA2, was generated and amplified in HEK-293T cells, which was purified over
CsCl gradients. HeLa cells that were grown to confluence in six-well plates were
infected at a multiplicity of infection (MOI) of 10 for 4 h in the serum-containing
medium. In order to control for any nonspecific effects of viral infection on HeLa
cell signaling, monolayers were infected in parallel with the adenovirus contain-
ing the empty shuttle vector. The infected cells were then used to measure the
level of PLC activation, as described below.
Measurement of total IPs. HeLa or Rat-1 cells were seeded at a density of 1.5
 104 cells/cm2. The HeLa cells were either transfected with 1 g of the LPA2
receptor plasmids with Lipofectamine or infected with the recombinant adeno-
virus expressing the LPA2 receptor at an MOI of 10. After 24 h, either Rat-1 cells
or HeLa cells were incubated with 1 Ci of [3H]inositol (NEN Life Science
Products)/well in 1 ml of inositol-free medium for 24 h at 37°C. After incubation
with 10 mM LiCl for 20 min, the cells were treated with the agonists for 20 min
and then fixed by adding ice-cold 5% perchloric acid. The accumulated [3H]
inositol phosphates (IPs) were determined as described previously (21). All of
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the assays were duplicated, and the radioactivity of the eluants was normalized to
the radioactivity of the total extract.
RESULTS
LPA2 interacts with NHERF2 in isoform-specific manner.
NHERF2 is classified as a type I PDZ domain-containing pro-
tein, which recognizes the S/T-X-I/V/L* motifs (“X” stands for
any amino acid, and the asterisk indicates the C-terminal res-
idue) (20). It was reported that several target proteins of
NHERF2 harbor a Leu residue in their C terminus (7, 10, 21,
24, 47). Interestingly, LPA2 contains the D-S-T-L motif at its C
terminus, whereas LPA1 and LPA3 have H-S-V-V and K-S-T-S
motifs, respectively. This information raised the possibility that
the molecular interaction may happen between NHERF2 and
the specific isoform of LPA receptor. In order to examine this
possibility, pull-down assays from rat kidney extracts were per-
formed by using GST-fused CT of the LPA receptors.
NHERF2 was coprecipitated with GST-LPA2-CT but with nei-
ther GST-LPA1-CT nor GST-LPA3-CT (Fig. 1A). In order to
determine whether NHERF2 associates with the full-length
LPA2 receptor in vivo, the interaction between LPA2 and
NHERF2 was then examined by the coimmunoprecipitation
method. NHERF2 was cotransfected with the Flag-tagged
forms of either LPA1 or LPA2 in the COS-7 cells, the cell
lysates were allowed to immunoreact with the anti-Flag anti-
body. Consistently, NHERF2 was coimmunoprecipitated by
Flag-LPA2 but not by Flag-LPA1 (Fig. 1B), suggesting a spe-
cific association of LPA2 with NHERF2.
The NHERF family contains two subtypes, NHERF1 and
NHERF2 (43). NHERF1 and NHERF2 were further exam-
ined to determine whether they commonly bind to LPA2. The
immobilized GST-fused proteins were incubated with the
MBP-fused LPA2-CT (Fig. 1C). It was found that MBP-LPA2
CT has a strong preference for NHERF2 over NHERF1. In
addition, this result was confirmed by immunoprecipitation
with Flag-LPA2 from the lysates of COS-7 cells cotransfected
with the HA-NHERF constructs. HA-NHERF2 was found to
interact significantly with Flag-LPA2, whereas HA-NHERF1
was not detected, which was attributed to its low affinity for
LPA2 (Fig. 1D). These results suggest that LPA2 binding is
specific for NHERF2 but not for NHERF1.
The interaction between LPA2 and NHERF2 requires both
the second PDZ domain of NHERF2 and the C-terminal PDZ-
binding motif of LPA2. First, we attempted to determine the
binding region of NHERF2 that are essential for the LPA2
association. Two different deletion mutants (P1-P2 and P2-C),
which were truncated at the C or N terminus, and three frag-
ments (P1, P2, and C), which contain the first PDZ, second
PDZ, or ERM-binding domains individually, were expressed in
His6-tagged forms. Several fragments of NHERF2 were immo-
bilized onto a Ni2-nitrilotriacetic acid resin and incubated
with the GST-LPA2-CT (Fig. 2A). The P1-P2 mutant, which
contains both PDZ domains, was found to interact equivalently
with the wild-type NHERF2. Interestingly, the deletion of the
first PDZ domain from the N terminus did not affect the
association with LPA2. Further successive analysis, using the
fragmented versions of NHERF2 such as P1, P2, and C, re-
vealed that LPA2-CT binds to P2 fragment specifically. These
results suggest that the second PDZ domain of NHERF2 is
required for the interaction with LPA2. The binding region of
NHERF2 was further confirmed in vivo by comparing the
wild-type NHERF2 with the second PDZ domain-deleted mu-
tant. As shown in Fig. 2B, Flag-LPA2 coimmunoprecipitated
wild-type NHERF2 but not the NHERF2 mutant with the
second PDZ domain deleted, suggesting that LPA2 forms a
molecular complex with NHERF2 via its second PDZ domain.
Second, we examined whether or not the interaction be-
tween LPA2 and NHERF2 essentially depends on the C-ter-
minal PDZ-binding motif of LPA2. The wild-type Flag-LPA2
was compared to its mutant, in which the C-terminal Leu
residue was substituted with Ala. As expected, a point muta-
tion (L3A) in the PDZ-binding motif of LPA2 abolished the
interaction with NHERF2 (Fig. 2C). Furthermore, the effect of
agonist stimulation on the interaction between two molecules
was examined. LPA stimulation did not induce any consider-
able change in the LPA2-NHERF2 interaction through all of
the time points examined. Therefore, these results indicate
that LPA2 exists in a molecular complex with NHERF2 in
resting cells regardless of the LPA stimulation.
The stable expression of NHERF2 increases LPA-induced
PLC- activation in Rat-1 cells. In order to reveal the func-
tional role of NHERF2 in LPA signaling, Rat-1 cell lines
overexpressing either wild-type NHERF2 (NHERF2 wild type
[NHERF2 WT]) or the NHERF2 mutant with the second PDZ
domain deleted (NHERF2 PDZ2) were established (Fig.
3A). In these cell lines, the NHERF1 expression levels were
not altered by NHERF2 expression. Previously, it was demon-
strated that LPA induces the LPA receptor-mediated PLC-
activation, which is followed by intracellular Ca2 mobilization
in a variety of cells (4, 8, 22, 23). Interestingly, we found that
LPA-induced IP generation was markedly potentiated by
the expression of the wild-type NHERF2. In contrast to the
wild-type NHERF2, the second PDZ domain-deleted mutant
of NHERF2 did not make any change on LPA-induced IP
generation, suggesting the importance of the second PDZ do-
main in the function of NHERF2 (Fig. 3B). Consistently, LPA-
induced Ca2 mobilization was markedly augmented by the
wild-type NHERF2 expression but not by either the vector or
the NHERF2 mutant expression (Fig. 3C). Furthermore, in-
tracellular Ca2 mobilization was completely abolished by the
presence of 5 M U73122, which is a specific PLC inhibitor.
These results indicate that NHERF2 expression potentiates
the LPA-induced PLC- activation, followed by intracellular
Ca2 mobilization in Rat-1 cells.
NHERF2 is required for the efficient LPA2-mediated PLC-
signaling in HeLa cells. The functional role of NHERF2 was
further confirmed in HeLa cells, in which NHERF2 was ex-
pressed endogenously. In addition, HeLa cells are ideal for
assessing the LPA2-mediated PLC activation because these
cells show low levels of a background LPA response and thus
allow LPA2 signaling to be studied after transfection. In order
to modulate the NHERF2 expression level in the HeLa cells,
the RNAi technique, which specifically silences the expression
of the endogenous genes in mammalian cells, was used. When
transfected with the siRNA duplexes directed against the re-
spective NHERF isoforms, the NHERF1 and NHERF2 ex-
pression levels were significantly decreased (Fig. 4A). This
effect of the siRNA transfection was specific for the respective
isoforms since it had no effect on the expressions of the other
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NHERF isoform. In addition, the expressions of PLC- iso-
forms or Flag-LPA2 were not affected by siRNA transfection.
Importantly, the knock-down of NHERF2 resulted in a
marked decrease in LPA2-mediated IP generation, suggesting
the functional significance of NHERF2 in LPA2-mediated
PLC- activation in HeLa cells (Fig. 4B). Furthermore, in
good agreement with the selective interaction of NHERF2
with LPA2 (Fig. 1D), LPA2-mediated IP generation was af-
FIG. 1. LPA2 interacts with NHERF2 in an isoform-specific manner. (A) NHERF2 binds to the CT of LPA2. The GST-fused CTs of three LPA
receptor isoforms (GST-LPA1-CT, GST-LPA2-CT, and GST-LPA3-CT) and GST (4 g) were immobilized onto glutathione beads, and incubated
with lysates (3 mg) from rat kidney. The resulting precipitates were subjected to SDS-PAGE and analyzed by Western blot analysis with
anti-NHERF2 antibody (upper panel) or by Ponceau S staining (lower panel). (B) Flag-LPA2, but not Flag-LPA1, coimmunoprecipitates
NHERF2. Flag-LPA1 or Flag-LPA2 was cotransfected with NHERF2 into COS-7 cells, as indicated. The cell lysates were immunoprecipitated with
anti-Flag antibody. The resulting precipitates were analyzed by Western blot analysis with anti-NHERF2 antibody (upper panel). The same blot
was reprobed with anti-Flag antibody to show the amount of precipitated LPA receptors (middle panel). The NHERF2 expression levels in the
total cell lysates are also shown (bottom panel). (C) Preferential interaction of GST-fused NHERF2 to LPA2-CT. MBP-fused LPA2-CT
(MBP-LPA2-CT) was incubated with GST or GST-fused NHERF isoforms (GST-NHERF1 and GST-NHERF2), which were immobilized on GSH
beads. The amounts of MBP-LPA2-CT bound to the GST-fused proteins were measured by SDS-PAGE and after Western blot analysis with
anti-MBP antibody (upper) or Ponceau S staining (lower). (D) HA-NHERF2, but not HA-NHERF1, is coimmunoprecipitated with LPA2. Either
HA-NHERF1 or HA-NHERF2 was transiently coexpressed with Flag-LPA2 in COS-7 cells. The cell lysates were immunoprecipitated with
anti-Flag antibody. After being washed, the resulting precipitates and total lysates were subjected to SDS-PAGE after immunoblot analysis with
anti-HA antibody or anti-Flag antibody, as indicated. These results are representative of at least two independent experiments.
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fected specifically by the knock-down of NHERF2 but not by
that of NHERF1. This suggests that NHERF2 plays an impor-
tant role in LPA2-mediated PLC- activation.
The importance of the direct interaction between LPA2 and
NHERF2 was next examined by comparing the wild-type LPA2
with its mutant, which was defective in terms of the interaction
with NHERF2. The wild-type LPA2 or its mutant (-DSTA) was
transfected into HeLa cells. Upon treatment with 1 M LPA,
IP accumulation increased markedly in the wild-type LPA2-
transfected cells, whereas its mutant (-DSTA) showed an
	70% reduction in IP accumulation (Fig. 5C). Despite the
significant difference in the LPA-induced PLC activation, the
expression levels of the wild-type LPA2 and of its mutant were
similar (Fig. 5C), and both endogenous PLC- and NHERF2
expression levels were unaffected by the transfection of LPA2
(data not shown). Therefore, the observed difference in the
activation of PLC- may have been caused by a point mutation
in the PDZ-binding motif of LPA2. These results indicate that
LPA2-mediated PLC- activation is modulated by the PDZ-
binding motif-dependent interaction of LPA2 with NHERF2.
NHERF2 couples LPA2 to PLC-3 specifically. In a previous
study, it was demonstrated that NHERF2 is associated with
PLC-3 (21). Moreover, several reports have suggested that
NHERF forms a multimeric complex within the cells due to
the dimerization of the PDZ domains (30, 33, 47). Therefore,
NHERF2 was examined to determine whether it enables LPA2
to be linked physically to PLC-3. NHERF2 was cotransfected
in combination with Flag-tagged PLC- isoforms into COS-7
cells and treated with 0.5 mM DSP, which is a cell permeable
cross-linker, as described by Lau and Hall (30). Thereafter, the
lysates were subjected to a pull-down assay with GST-
LPA2-CT and GST as the control. As shown in Fig. 5A,
PLC-3 was coprecipitated with GST-LPA2 CT in the pres-
ence of NHERF2 but not in its absence. On the other hand,
PLC-1 was not detected despite the presence of NHERF2. In
a good agreement with the above results, it was found that
Flag-LPA2 coimmunoprecipitated endogenous PLC-3, along
with NHERF2 in HeLa cells. In contrast, PLC-1 was not
detected in the precipitates (Fig. 5B). This suggests that
FIG. 2. The interaction between LPA2 and NHERF2 requires both the second PDZ domain of NHERF2 and the C-terminal PDZ-binding
motif of LPA2. (A) Six His-NHERF2 (WT) and its fragments (P1, the first PDZ domain; P2, the second PDZ domain; and C, the C-terminal
fragment of NHERF2) were immobilized on Ni2-affinity resin and subsequently incubated with the GST-LPA2-CT. The amounts of GST-
LPA2-CT bound to the immobilized proteins were measured by SDS-PAGE, followed by Western blot analysis with anti-GST antibody. (B)
Flag-LPA2 was cotransfected with either wild-type NHERF2 (NHERF2 WT) or the second PDZ-deleted form (NHERF2 PDZ2), as indicated.
The cell lysates were immunoprecipitated with anti-Flag antibody. The resulting precipitates were analyzed by Western blot analysis with the
anti-NHERF2 antibody (left, upper) to detect the precipitated NHERF2 WT or NHERF2 PDZ2. The same blot was reprobed with anti-Flag
antibody (left, lower) to show the amount of precipitated LPA2. The expression levels of NHERF2 WT and of NHERF2 PDZ2 within the total
cell lysates are also shown (right). (C) NHERF2 was cotransfected with wild-type Flag-LPA2 (Flag-LPA2 WT) or its mutant form (Flag-LPA2 Mut)
into COS-7 cells, as indicated. The transfected cells were serum deprived for 24 h prior to treatment with 1 M LPA in 0.1% BSA for the indicated
times. After being washed with ice-cold phosphate-buffered saline (PBS), the cells were lysed and immunoprecipitated with anti-Flag antibody. The
resulting precipitates (top, middle) and total lysates (bottom) were analyzed by Western blot analysis with either anti-NHERF2 antibody or
anti-Flag antibody, as indicated. These results are representative of three independent experiments.
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NHERF2 mediates the physical and specific interaction of
LPA2 with PLC-3 but not with PLC-1.
LPA2 was then examined to determine whether it is func-
tionally coupled to PLC-3 isoform. When analyzed for the
endogenous PLC- isoforms, HeLa cells were found to express
both PLC-1 and PLC-3 isoforms (Fig. 5B), whereas the
other PLC- isoforms were not detected by Western blot anal-
ysis (data not shown). The present study developed siRNAs,
which were directed against respective PLC- isoforms (Fig.
5C). After transfection with the siRNA duplexes, the expres-
sions of either PLC-1 or PLC-3 were specifically reduced to
ca. 80 to 90% of the control cell level. Upon LPA stimulation,
accumulation of the IPs was severely affected by PLC-3
knock-down but not by PLC-1 knock-down (Fig. 5D). There-
fore, these results indicate the functional and specific coupling
between LPA2 and PLC-3 isoform.
NHERF2 potentiates LPA-induced ERK activation and
COX-2 induction. The potential influence of NHERF2 expres-
sion on MAPK pathway was next examined. As shown in Fig.
6A, LPA-induced ERK activation was strongly enhanced by
NHERF2 expression in Rat-1 cells. Moreover, the potentiation
of ERK activity was reversed by pretreating the cells with 5 M
U73122, which is a PLC inhibitor. This suggests that an in-
crease in PLC- signaling is responsible for the NHERF2-
dependent amplification of ERK activation. In addition, the
present study examined whether or not the enhanced ERK
activation has an effect on the expression of the downstream
target genes. Cyclooxygenase-2 (COX-2) is an inducible form
of cyclooxygenase and is known to be upregulated in a MAPK-
dependent manner (39). In response to 5 M LPA in 0.1%
bovine serum albumin (BSA), COX-2 expression was strongly
induced by NHERF2 expression in Rat-1 cells but not by either
the vector or the second PDZ-deleted form (Fig. 6B). In con-
trast, epidermal growth factor (EGF)-induced COX-2 expres-
sion was similar in the three cell lines, suggesting a specific role
of NHERF2 in LPA signaling. Moreover, this induction of the
FIG. 3. NHERF2 increases LPA-induced IP generation and subsequent Ca2 mobilization in Rat-1 cells. (A) Rat-1 cells were stably transfected
with vector alone (Vector), NHERF2 WT, and the second PDZ domain-deleted mutant (NHERF2 PDZ2), individually. The NHERF2 (upper)
and NHERF1 (lower) expression levels were determined by Western blot analysis with the specific antibodies against each isoform of NHERF,
as indicated. (B) Rat-1 cell lines were split at a density of 3  105 cells/well, which were then loaded with 1 Ci of [3H]inositol/ml for 24 h at 37°C
and stimulated with LPA at the indicated concentrations. The generation of [3H]IPs was determined as described in Materials and Methods. The
data are presented as means
 the standard errors (SE) of three separate experiments performed in duplicate. (C) LPA-induced Ca2 mobilization
in Rat-1 cell lines. Rat-1 cells were loaded with 1 M Fluo-3/AM for 30 min at 37°C, washed twice with prewarmed Ca2-free Locke’s solution,
and then stabilized for 5 min under a microscope. Fluorescence confocal microscopic images of the cytosolic Ca2 mobilization of Rat-1 cell lines
were captured sequentially before () and after () the addition of 10 M LPA (magnification, 200) and in the presence or absence of 5 M
U73122, as indicated. Ca2-sensitive fluorescence images of each of the Rat-1 cells were subjected to densitometry over time (right). The results
shown are those of a single experiment that is representative of three experiments performed with independent preparations.
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COX-2 gene was blocked by PD98059, which is a specific
inhibitor of the MEK/ERK signaling pathway, indicating the
involvement of the ERK pathways in this process. These re-
sults suggest that NHERF2-dependent potentiation of PLC-
signaling augments the LPA-induced ERK activation and the
subsequent COX-2 induction in Rat-1 cells.
DISCUSSION
NHERF2-dependent regulation of LPA2-mediated PLC- ac-
tivation. In the present study, we demonstrated that NHERF2
specifically interacts with LPA2 in an isoform-specific manner.
Although it is known that NHERF1 and NHERF2 share the
majority of their target proteins (16, 17, 29, 33), there is a line
of evidence suggesting a specific association of NHERF2 with
several target molecules, such as plasma membrane Ca2 AT-
Pase isoform 2b (PMCA2b), PLC-3, TAZ, -actinin-4, and
serum/glucocorticoid-regulated protein kinase (7, 10, 21, 24,
27, 47). It is therefore interesting that NHERF2 specifically
regulates the LPA2 signaling through the selective interaction.
Therefore, these results provide the evidence that NHERF2
has a distinctive role in signal transduction that is not dupli-
cated by NHERF1. LPA has been reported to stimulate PLC-
activation via its cognate receptors: LPA1, LPA2, and LPA3 (3,
4, 22, 23). In addition, when examined in mouse embryo fibro-
blast cells, which were derived from knockout mice, both LPA1
and LPA2 were shown to mediate PLC- activation in re-
sponse to LPA stimulation (8). These reports suggest that the
LPA receptors commonly have an intrinsic ability to induce
PLC- activation in various types of cells. However, they ap-
pear to vary in the relative strength of agonist-induced PLC-
signaling events, involving Ca2 mobilization and PKC activa-
tion, according to the cell types examined (3, 4, 8, 12, 22, 23).
In this regard, it is interesting that NHERF2 interacts specif-
ically with LPA2 and may provide a mechanism by which LPA2
intensifies PLC- activation. Therefore, these results suggest
that LPA receptor-mediated PLC- activation might be differ-
entially regulated by the specific coupling with not only the G
proteins but also additional regulatory factors, such as NHERF2.
Although it is not known how NHERF2 increases the LPA-
induced PLC- activity, we suggest that NHERF2 acts as a
scaffolding protein. It was shown here that PLC-3 is included
in the same protein complex with LPA2 and NHERF2 (Fig. 5A
and B). We previously reported that PLC-3 contains a C-
terminal PDZ domain-binding motif and directly associates
with the second PDZ domain of NHERF2 (21). In the absence
FIG. 4. NHERF2 is required for the efficient LPA2-mediated PLC- activation in HeLa cells. (A) Gene silencing of either the NHERF1 or
NHERF2 with siRNAs. HeLa cells were transfected with siRNAs directed against NHERF1 or NHERF2 or with a control siRNA (Luciferase
GL3), as described in Materials and Methods. One day after the siRNA transfection, the cells were split at a density of 2  105 cells/well. After
24 h, the cells were infected with the recombinant adenovirus expressing Flag-LPA2. After 24 h postinfection, the HeLa cells were lysed and
analyzed by Western blot with the specific antibodies as indicated. These results were representative of three independent experiments. (B) Effects
of NHERF2 gene silencing on LPA2-mediated PLC- activation in HeLa cells. After 12 h postinfection, the infected cells were labeled with 1 Ci
of [3H]inositol/ml for 12 h at 37°C, treated with either 0.1% BSA only () or 1 M LPA-BSA conjugates (), and then analyzed for [3H]IPs as
described in Materials and Methods. The data are presented as means 
 the SE of three separate experiments performed in duplicate. (C) The
effects of a mutation at the C-terminal PDZ-binding motif of LPA2 on LPA-induced IPs generation in HeLa cells. HeLa cells were transfected
with the indicated constructs (Vector, control vector; LPA2 WT, wild-type LPA2; LPA2 Mut, mutant LPA2). At 24 h posttransfection, the cells were
labeled with [3H]inositol for 12 h and treated with either 0.1% BSA only () or 1 M LPA-BSA conjugates (). The generation of IPs was
analyzed as described previously. The results are presented as means 
 SE obtained from three separate experiments performed in duplicate. In
addition, the expressions of Flag-LPA2 WT and Flag-LPA2 Mut were analyzed by immunoprecipitation and subsequent Western blot analysis with
anti-Flag antibody (inside the graph).
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FIG. 5. NHERF2 couples LPA2 to PLC-3 specifically. (A) LPA2 forms a molecular complex with PLC-3 in a NHERF2-dependent manner.
The NHERF2 constructs (NHERF2, NHERF2 WT; NHERF2 PDZ2, the second PDZ domain-deleted form) were cotransfected in combination
with either Flag-PLC-3 (left) or Flag-PLC-1 (right) as indicated. After 2 days, COS-7 cells were washed and incubated with PBS containing 0.5
mM DSP (Pierce), which is a cell-permeable cross-linker, for 30 min. After the residual DSP was blocked with PBS containing 50 mM Tris buffer,
the cleared lysates were subjected to a pull-down assay using GST-LPA2-CT immobilized onto GSH beads. After a washing step, the resulting
precipitates were subjected to SDS-PAGE and then analyzed by Western blot analysis with anti-Flag antibody (top) and anti-NHERF2 antibody
(middle) or by Ponceau S staining (bottom) as indicated. The results are representative of three independent experiments. (B) Specific coimmu-
noprecipitation of PLC-3 and not of PLC-1 with Flag LPA2. HeLa cells (at a density of 6  10
6 cells/150-mm dish) were infected with either
the recombinant Flag-LPA2 adenovirus or control empty virus at an MOI of 10. At 24 h postinfection, the infected cells were incubated with PBS
containing 0.5 mM DSP for 30 min. After the cell lysates were blocked with 50 mM Tris buffer, they were immunoprecipitated with anti-Flag
antibody. After a washing step, the resulting precipitates were analyzed with the specific antibodies as indicated. (C) Gene silencing of PLC- isoforms
with specific siRNAs. HeLa cells were transfected with siRNAs directed against PLC-1 or PLC-3, along with control siRNA (Luciferase), as
described in Materials and Methods. After 3 days, the HeLa cells were lysed and then analyzed by Western blot analysis with specific antibodies,
as indicated. (D) PLC-3 is functionally coupled to LPA2. At 24 h after siRNA transfection, the cells were split at a density of 2  10
5 cells/35-mm
well and infected with recombinant adenovirus expressing Flag-LPA2 for 4 h. At 12 h after viral infection, the infected cells were labeled with 1
Ci of [3H]inositol/ml for 12 h and treated with either 0.1% BSA only () or 1 M LPA-BSA conjugates (). The generation of [3H]IPs was
analyzed as described in Materials and Methods. The results are presented as means 
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of NHERF2, both LPA2 and PLC-3 may be nonassociated,
which limits the signal transduction between them. In contrast,
in the presence of NHERF2, LPA2 and PLC-3 may be phys-
ically coupled in the protein complex, thus enabling LPA2 to
trigger PLC-3 signaling efficiently. However, these findings
raise a question as to how both PLC-3 and LPA2 bind to the
same region (the second PDZ domain) of NHERF2. One
possible explanation is that LPA2 and PLC-3 bind to different
NHERF2 molecules in the same protein complex. Recently,
several reports have demonstrated that NHERF1 or NHERF2
dimerizes via the PDZ domain-mediated interactions (30, 33,
47). Therefore, these results suggest that the self-association of
NHERF2 may be essential for the formation of a protein
complex containing LPA2 and PLC-3.
NHERF2-dependent specific coupling of LPA2 to PLC-3.
Mammals possess four PLC- isoforms, namely, 1 to 4 (37),
which are known to have quite distinct physiological roles (26).
We found here that LPA2 is coupled to PLC-3 in an isoform-
specific manner. A large body of evidence suggests that the
PLC- isoforms are selectively activated by extracellular
GPCR agonists (2, 14, 41, 42). It has been generally assumed
that this selectivity might be due to either a cell type-specific
distribution of PLC- isoforms or the G-protein subclass in-
volved (37). However, both PLC-1 and PLC-3 are com-
monly expressed in several cell lines, including Rat-1 and HeLa
cells, which were used in the present study. With respect to the
G-protein sensitivity, it is known that both PLC-1 and
PLC-3 are stimulated by GTPS-bound Gq to similar ex-
tents in vitro (40). Furthermore, LPA2-mediated PLC activa-
tion is either insensitive or partially sensitive to pertussis toxin
according to the cells examined, which suggests that LPA2
couples to Gq primarily to activate PLC- (4, 23). In this
regard, neither the differential distribution of PLC- isoforms
nor the distinct activation of the G-protein subclass is likely to
be a satisfactory explanation for the PLC- selectivity of LPA2.
Therefore, isoform-selective coupling appears to involve a
mechanism different from those described previously. In light
of our pull-down assay results (Fig. 5A and B), which show that
LPA2 can form a ternary complex with PLC-3 but not with
PLC-1, the signaling specificity is probably conferred by the
selective scaffolding of the sequential signal transducers. This
selectivity of the PLC- isoform is consistent with the higher
degree of preference of NHERF2 for PLC-3 over PLC-1, as
was reported previously (21). Accordingly, such interactions
with NHERF2 may also influence the specificity of LPA2-
FIG. 6. NHERF2 potentiates LPA-induced ERK activation and COX-2 induction. (A) Rat-1/vector and Rat-1/NHERF2 WT cells were serum
deprived for 24 h and then treated with the LPA-BSA conjugates at the indicated concentrations for 10 min. Independently, Rat-1/NHERF2 WT
cells were pretreated with dimethyl sulfoxide () or 5 M U73122 () for 20 min and then treated with 1 M LPA in 0.1% BSA for 10 min. The
cell lysates (20 g) were subjected to SDS-PAGE and analyzed with either anti-pERK antibody or anti-ERK antibody. The results shown are
representative of three independent experiments. (B) Serum-deprived Rat-1 cell lines (vector, NHERF2 WT, and NHERF2 PDZ2) were treated
with 5 M LPA or with 50 ng of EGF/ml for 10 h at 37°C. In an independent experiment, Rat-1/NHERF2 WT cells were pretreated with dimethyl
sulfoxide () or 30 M PD98059 () for 30 min and then treated with 5 M LPA for 10 h at 37°C. The cell lysates (20 g) were subjected to
SDS-PAGE and analyzed by Western blot with anti-COX-2 antibody or anti-actin antibody as indicated. The results shown are those of a single
experiment, which is representative of three experiments performed with independent preparations.
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mediated PLC- activation by holding LPA2 and PLC-3 in
close proximity.
Potential physiological consequence of NHERF2-dependent
regulation of LPA2 signaling. PLC- is involved in MAPK
activation by IP3-dependent Ca
2 mobilization and DAG-de-
pendent PKC activation (5, 35). Moreover, GPCR agonists,
including LPA and carbachol, have been shown to activate
ERK in a PLC-dependent manner (25, 32). The present study
found that NHERF2 potentiates the LPA-induced ERK acti-
vation, followed by COX-2 induction in Rat-1 cells via a PLC-
dependent pathway. It is known that COX-2 is upregulated in
a MAPK-dependent manner in response to cytokines, growth
factors, and other stimuli and plays a key role as a mediator of
proliferation and inflammation (28, 39). Furthermore, whereas
NHERF2 upregulates LPA-driven COX-2 induction, EGF-
driven induction is unaffected. This indicates that NHERF2
specifically increases LPA-stimulated COX-2 induction by in-
teracting directly with LPA2, since EGF receptor does not
contain a PDZ domain-binding motif at its C terminus. There-
fore, these results suggest that NHERF2 may play an impor-
tant role in regulating LPA2-mediated downstream signaling
such as the PLC-/ERK/COX-2 pathway. LPA and its recep-
tors are known to be multifunctional in a variety of normal cell
physiologies (34, 36). In addition, several reports have sug-
gested a role for LPA/LPA2 signaling in the pathogenesis, such
as in tumor formation and cancer development (11, 13, 38, 46).
In this regard, the current observation that NHERF2 potenti-
ates the LPA2 signaling events such as PLC-Ca
2/PKC, ERK,
and COX-2 induction implies a broad connection of NHERF2
in the regulation of LPA/LPA2-mediated pathological, physi-
ological responses, including cell proliferation, inflammation,
and tumor progression.
In summary, it was found that LPA2 interacts with NHERF2
in an isoform-specific manner and provided evidence that
NHERF2 functions as a molecular scaffold, which defines the
specificity and efficiency of LPA2-mediated PLC-3 activation.
A schematic view of LPA2 signaling emerging from the present
study is depicted in Fig. 7. The results suggest that a ternary
complex of LPA2, NHERF2, and PLC-3 plays a pivotal role
in the organization and modulation of the LPA2-mediated
PLC signaling pathway.
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